Assessing the impact of vaccination and medical resource allocation on infectious disease outbreak management: a case study of COVID-19 in Taiyuan City.

Publication date: Aug 26, 2024

Amidst an emerging infectious disease outbreak, the rational allocation of vaccines and medical resources is crucial for controlling the epidemic’s progression. Analysing COVID-19 data in Taiyuan City from December 2022 to January 2023, this study constructed a dynamics model to assess the impact of COVID-19 vaccination and resource allocation on epidemic trends. Vaccination significantly reduces infection rates, hospitalisations, and severe cases, while also curtailing strain on medical resources by reducing congestion periods. An early and sufficient reserve of medical resources can delay the onset of medical congestion, and with increased maximum capacity of medical resources, the congestion’s end can be accelerated. Stronger resource allocation capabilities lead to earlier congestion resolution within a fixed total resource pool. Integrating vaccination and medical resource allocation can effectively reduce medical congestion duration and alleviate the epidemic’s strain on medical resource capacity (CCMR).

Open Access PDF

Concepts Keywords
December China
Pool China
Severe COVID-19
Vaccination COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Disease Outbreaks
Health Care Rationing
Humans
medical resource allocation
Resource Allocation
SARS-CoV-2
Vaccination
vaccination

Semantics

Type Source Name
disease VO vaccination
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH COVID-19
disease MESH emerging infectious disease
disease MESH infection
disease MESH Birth Defect
disease MESH panic
disease MESH death
disease VO population
drug DRUGBANK Coenzyme M
drug DRUGBANK Guanosine
disease VO effective
disease IDO production
disease VO efficiency
disease VO organization
drug DRUGBANK Etoperidone
disease VO vaccine
disease IDO process
disease VO dose
disease VO vaccine dose
drug DRUGBANK Spinosad
disease VO vaccinated
disease MESH asymptomatic infections
disease VO time
disease IDO contagiousness
disease IDO susceptible population
disease MESH critical illness
disease IDO infected population
disease VO dead
drug DRUGBANK Albendazole
disease VO Gap
disease VO unvaccinated
disease VO effectiveness
disease MESH Coronavirus Infection
disease VO manufacturer
disease MESH dengue
disease VO Optaflu
disease VO vaccine efficacy
disease VO efficient
drug DRUGBANK Carboxyamidotriazole
disease MESH uncertainty
disease MESH Clinical progression
drug DRUGBANK Ranitidine
disease MESH influenza

Original Article

(Visited 1 times, 1 visits today)